EDGAR·FLOW

CLOVER HEALTH INVESTMENTS, CORP. /DE — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Clover Health released a shareholder Q&A addressing Q3 2026 results (November 16, 2026). Key specifics: ~159k insurance members at end of Q3 2026; company expects 100–150 basis points of Adjusted SG&A improvement year-over-year for full year 2026 and believes material further improvement is possible from fixed-cost leverage as membership grows. Counterpart Assistant (CA) achieved ~1,500 basis-point MCR advantage historically; CA associated with 18-month earlier CKD diagnosis and 18% fewer hospitalizations, 25% fewer 30-day readmissions in heart failure patients. No new market entry announced; company reaffirmed focus on New Jersey (market share risen from ~20% to 31% non-SNP) and Georgia, with Counterpart expansion into third-party payers/providers ongoing but no contracted lives or timelines disclosed.
Why this rating

Routine supplemental disclosure; no new material events, contracts, or guidance changes. Strategic talking points and forward-looking aspirations, not binding commitments or earnings/membership surprises relative to company's $1.1B scale.

View original filing on SEC.gov ↗ CLOV · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.